Clear All
773 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9306 Pertuzumab Perjeta 1 mg Immunotherapy Monoclonal Antibody HER2 No 2012 Jan 1, 2014 In Use
NA Cabozantinib Cabometyx 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J1726 Hydroxyprogesterone Caproate Makena 10 mg Hormonal Therapy Progestin No 2011 Jan 1, 2018 In Use
J1729 Hydroxyprogesterone Caproate Hydroxyprogesterone Caproate 10 mg Hormonal Therapy Progestin No 2011 Jan 1, 2018 In Use
NA Ruxolitinib Jakafi 15 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Ruxolitinib Jakafi 5 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
C9289 Asparaginase Erwinaze 1,000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 2011 Apr 4, 2012 Dec 31, 2014 No Longer Used
C9284 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jul 1, 2011 Dec 31, 2011 No Longer Used
J9042 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan 1, 2013 In Use
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
J9228 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jan 1, 2012 In Use
NA Ruxolitinib Jakafi 25 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
J1725 Hydroxyprogesterone Caproate Hydroxyprogesterone Caproate 1 mg Hormonal Therapy Progestin No 2011 Jan 1, 2012 In Use
NA Vemurafenib Zelboraf 240 mg Chemotherapy Enzyme Inhibitor BRAF Yes 2011 In Use
C9287 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan 1, 2012 Dec 31, 2012 No Longer Used
NA Ruxolitinib Jakafi 10 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Vandetanib Caprelsa 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
J9019 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 2011 Jan 1, 2013 Jan 1, 2026 In Use
NA Abiraterone acetate Zytiga 250 mg Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Yes 2011 In Use
J9196 Gemcitabine HCl (Accord) Gemcitabine 200MG Chemotherapy Antimetabolite Pyrimidine Analog No 2011 Mar 17, 2023 In Use
C9280 Eribulin mesylate Halaven 1 mg Chemotherapy Antimitotic Agent Furopyrans No 2010 Apr 1, 2011 Dec 31, 2011 No Longer Used
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Jul 1, 2011 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.